- Home
- XBIT vs PRLD Comparison
XBIT vs PRLD Comparison
Compare XBIT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- PRLD
- Stock Information
- Founded
- XBIT 2005
- PRLD 2016
- Country
- XBIT United States
- PRLD United States
- Employees
- XBIT N/A
- PRLD N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- XBIT Health Care
- PRLD Health Care
- Exchange
- XBIT Nasdaq
- PRLD Nasdaq
- Market Cap
- XBIT 82.3M
- PRLD 69.1M
- IPO Year
- XBIT 2015
- PRLD 2020
- Fundamental
- Price
- XBIT $2.49
- PRLD $1.19
- Analyst Decision
- XBIT
- PRLD Strong Buy
- Analyst Count
- XBIT 0
- PRLD 3
- Target Price
- XBIT N/A
- PRLD $4.00
- AVG Volume (30 Days)
- XBIT 64.5K
- PRLD 303.3K
- Earning Date
- XBIT 11-12-2025
- PRLD 11-05-2025
- Dividend Yield
- XBIT N/A
- PRLD N/A
- EPS Growth
- XBIT N/A
- PRLD N/A
- EPS
- XBIT N/A
- PRLD N/A
- Revenue
- XBIT N/A
- PRLD $7,000,000.00
- Revenue This Year
- XBIT N/A
- PRLD N/A
- Revenue Next Year
- XBIT N/A
- PRLD N/A
- P/E Ratio
- XBIT N/A
- PRLD N/A
- Revenue Growth
- XBIT N/A
- PRLD N/A
- 52 Week Low
- XBIT $2.35
- PRLD $0.61
- 52 Week High
- XBIT $8.32
- PRLD $1.96
- Technical
- Relative Strength Index (RSI)
- XBIT 34.82
- PRLD 44.82
- Support Level
- XBIT $2.41
- PRLD $1.15
- Resistance Level
- XBIT $2.61
- PRLD $1.42
- Average True Range (ATR)
- XBIT 0.09
- PRLD 0.15
- MACD
- XBIT -0.00
- PRLD -0.03
- Stochastic Oscillator
- XBIT 36.35
- PRLD 8.33
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.